Prevalence and Profile of Aspirin Resistance in Hemodialysis Patients
Completed
- Conditions
- Aspirin Resistance
- Registration Number
- NCT00792272
- Lead Sponsor
- Northwell Health
- Brief Summary
Dialysis patient could be more aspirin resistant than the general population based on data from chronic kidney disease patients
- Detailed Description
We will try to describe the profile of aspirin resistant patient in hemodialysis patients
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- all hemodialysis patients on aspirin
Exclusion Criteria
- low platelets <100.000
- coagulopathy, bleeding disorders
- patient on plavix
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Aspirin Resistance in Hemodialysis patients 2 months
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie aspirin resistance in hemodialysis patients with chronic kidney disease?
How does aspirin resistance in hemodialysis patients compare to standard antiplatelet therapies like clopidogrel in terms of clinical outcomes?
Are specific biomarkers such as COX-1 or COX-2 expression levels predictive of aspirin resistance in end-stage renal disease populations?
What adverse events are associated with aspirin resistance in hemodialysis patients and how can they be mitigated?
What combination therapies or alternative antiplatelet agents are being explored for aspirin-resistant hemodialysis patients?